Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YELLIANN RUIZ IRIZARRY

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1083846893
CMS profile
508170
Location
PALMETTO BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$325.62

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $325.62 7

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YELLIANN RUIZ IRIZARRY

NPI 1083846893 · CMS profile ID 508170

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PALMETTO BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083846893?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YELLIANN RUIZ IRIZARRY, NPI 1083846893, CMS profile ID 508170. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083846893?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). YELLIANN RUIZ IRIZARRY, NPI 1083846893, CMS profile ID 508170. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083846893?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
YELLIANN RUIZ IRIZARRY, NPI 1083846893, CMS profile ID 508170, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1083846893?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $325.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mallinckrodt Enterprises LLC $29.0412/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704750063 CMS
Radius Health, Inc. $21.8811/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683962933 CMS
E.R. Squibb & Sons, L.L.C. $115.2010/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651356599 CMS
GlaxoSmithKline, LLC. $18.0010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670280545 CMS
E.R. Squibb & Sons, L.L.C. $97.7109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651356595 CMS
Novartis Pharmaceuticals Corporation $24.8208/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659947783 CMS
Janssen Biotech, Inc. $18.9705/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718864499 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $325.62 7
PY2020 $101.85 4
PY2021 $35.84 2
PY2022 $58.26 3
PY2023 $1,055.20 45
PY2024 $1,733.58 85
PY2025 $1,822.84 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $36,513.46 10
PY2022 Principal investigator $221,229.09 69
PY2021 Principal investigator $435,565.89 32
PY2020 Principal investigator $63,547.60 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $108.62 12/31/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 965540029
Principal investigator 1 GlaxoSmithKline, LLC. $7,029.00 12/23/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 965505491
Principal investigator 1 ABBVIE INC. $1,927.37 11/08/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889818903
Principal investigator 1 GlaxoSmithKline, LLC. $4,686.30 10/18/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A MULTI-CENTRE LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFI No dispute reported 06/30/2026 943969687
Principal investigator 1 GlaxoSmithKline, LLC. $2,482.20 09/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969937
Principal investigator 1 GlaxoSmithKline, LLC. $76.50 09/02/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969725
Principal investigator 1 ABBVIE INC. $1,556.58 08/11/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889805695
Principal investigator 1 GlaxoSmithKline, LLC. $12,700.80 08/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969839
Principal investigator 1 ABBVIE INC. $1,556.58 07/14/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889800875
Principal investigator 1 ABBVIE INC. $1,604.32 07/07/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889799305
Principal investigator 1 GlaxoSmithKline, LLC. $5,574.60 07/05/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969791
Principal investigator 1 ABBVIE INC. $4,379.02 06/07/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889793917
Principal investigator 1 GlaxoSmithKline, LLC. $7,007.40 06/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969825
Principal investigator 1 GlaxoSmithKline, LLC. $8,607.60 05/02/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969947
Principal investigator 1 ABBVIE INC. $2,073.13 04/05/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889783503
Principal investigator 1 GlaxoSmithKline, LLC. $1,786.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969693
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969717
Principal investigator 1 GlaxoSmithKline, LLC. $1,786.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969731
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969767
Principal investigator 1 GlaxoSmithKline, LLC. $2,758.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969845
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969857
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969875
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969899
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969905
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969913
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969925
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/24/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969977
Principal investigator 1 ABBVIE INC. $3,113.16 03/08/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889779965
Principal investigator 1 GlaxoSmithKline, LLC. $85.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969675
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969705
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969711
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969737
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969755
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969773
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969779
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969785
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969801
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969819
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969833
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969869
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969881
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969887
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969893
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969919
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969931
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969942
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969959
Principal investigator 1 GlaxoSmithKline, LLC. $174.10 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969991
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 03/01/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969997
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969663
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969669
Principal investigator 1 GlaxoSmithKline, LLC. $2,241.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969681
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969699
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969743
Principal investigator 1 GlaxoSmithKline, LLC. $2,241.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969749
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969761
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969795
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969807
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969813
Principal investigator 1 GlaxoSmithKline, LLC. $1,006.40 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969851
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969863
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969953
Principal investigator 1 GlaxoSmithKline, LLC. $85.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969965
Principal investigator 1 GlaxoSmithKline, LLC. $541.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969971
Principal investigator 1 GlaxoSmithKline, LLC. $85.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943969983
Principal investigator 1 GlaxoSmithKline, LLC. $606.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943970003
Principal investigator 1 GlaxoSmithKline, LLC. $306.00 01/26/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER INC
A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN No dispute reported 06/30/2026 943970007
Principal investigator 1 ABBVIE INC. $3,113.16 01/06/2022 Non-covered Recipient Entity
INNOVATION MEDICAL RESEARCH CENTER
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2) No dispute reported 06/30/2026 889772109
Principal investigator 1 Navidea Biopharmaceuticals, Inc. $123,919.25 01/05/2022 Non-covered Recipient Entity
Innovation Medical Research Center, Inc.
Development of a Normative Database for Rheumatoid Arthritis Imaging with Tc99m Tilmanocept No dispute reported 06/30/2026 940586407